SEC Tracker
Get the app

Surrozen SRZN

Surrozen reports Q3 2026 financial results

Surrozen (SRZN) filed an 8-K with the SEC on Nov 9, 2026, 4:19 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. First patient dosed in DUET Phase 1b study
  2. DUET Phase 2a enrollment expanded to 150 patients
  3. Cash runway extended to 2029
  4. Net loss of $129.7 million for Q3 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Surrozen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.